Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow‐up

Should autotransplantation in acute myeloid leukemia in first complete remission be revisited?

“…With a long-term follow-up of at least 14 years [7], 38% of 285 patients with favorable or intermediate risk AML, who were prospectively planned for ASCT, are in continuous remission, confirming the curative potential of ASCT in a substantial number of AML patients. This outcome is even more impressive, considering that it is an intention-to-treat analysis and that only 42% actually underwent ASCT and the procedure was performed between 1988 and 1996, when the attendant mortality from ASCT exceeded 10%.…”